NGL Fine-Chem Limited

NSEI:NGLFINE Stock Report

Market Cap: ₹11.4b

NGL Fine-Chem Valuation

Is NGLFINE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NGLFINE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NGLFINE (₹1837.25) is trading above our estimate of fair value (₹32.06)

Significantly Below Fair Value: NGLFINE is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NGLFINE?

Key metric: As NGLFINE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NGLFINE. This is calculated by dividing NGLFINE's market cap by their current earnings.
What is NGLFINE's PE Ratio?
PE Ratio27.5x
Earnings₹413.64m
Market Cap₹11.39b

Price to Earnings Ratio vs Peers

How does NGLFINE's PE Ratio compare to its peers?

The above table shows the PE ratio for NGLFINE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18x
524280 Kopran
19.7xn/a₹10.4b
531633 Lincoln Pharmaceuticals
13xn/a₹12.6b
506197 Bliss GVS Pharma
22.2xn/a₹14.1b
506260 Anuh Pharma
17xn/a₹10.0b
NGLFINE NGL Fine-Chem
27.5xn/a₹11.4b

Price-To-Earnings vs Peers: NGLFINE is expensive based on its Price-To-Earnings Ratio (27.5x) compared to the peer average (18x).

Price to Earnings Ratio vs Industry

How does NGLFINE's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.5xn/aUS$67.74m
524652 Ind-Swift
2xn/aUS$13.11m
No more companies available in this PE range
NGLFINE 27.5xIndustry Avg. 34.2xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NGLFINE is good value based on its Price-To-Earnings Ratio (27.5x) compared to the Indian Pharmaceuticals industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is NGLFINE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NGLFINE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NGLFINE's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,196.05

7D

0.8%

1Y

-22.8%

Colinz Laboratories

₹141.3m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹56.10

7D

3.0%

1Y

37.2%